BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 29650332)

  • 1. Clinicopathological and prognostic significance of MUC13 and AGR2 expression in intraductal papillary mucinous neoplasms of the pancreas.
    Mito K; Saito M; Morita K; Maetani I; Sata N; Mieno M; Fukushima N
    Pancreatology; 2018 Jun; 18(4):407-412. PubMed ID: 29650332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic study of the MIB-1 labeling index (Ki67) and postoperative prognosis for intraductal papillary mucinous neoplasms and ordinary ductal adenocarcinoma.
    Takeshita A; Kimura W; Hirai I; Takasu N; Moriya T; Tezuka K; Watanabe T
    Pancreas; 2012 Jan; 41(1):114-20. PubMed ID: 22143341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade.
    Michaels PJ; Brachtel EF; Bounds BC; Brugge WR; Pitman MB
    Cancer; 2006 Jun; 108(3):163-73. PubMed ID: 16550572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct patterns of peritumoral histological findings in subtypes of intraductal papillary mucinous neoplasms of the pancreas.
    Saito M; Imada H; Suzuki T; Sata N; Yasuda Y; Maetani I; Fukushima N
    Ann Diagn Pathol; 2015 Oct; 19(5):347-52. PubMed ID: 26265194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.
    Morimatsu K; Aishima S; Yamamoto H; Hayashi A; Nakata K; Oda Y; Shindo K; Fujino M; Tanaka M; Oda Y
    Hum Pathol; 2013 Sep; 44(9):1714-21. PubMed ID: 23597774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas.
    Oda Y; Aishima S; Morimatsu K; Hayashi A; Shindo K; Fujino M; Mizuuchi Y; Hattori M; Tanaka M; Oda Y
    Hum Pathol; 2013 Aug; 44(8):1487-98. PubMed ID: 23465281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
    Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
    Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas.
    Basturk O; Chung SM; Hruban RH; Adsay NV; Askan G; Iacobuzio-Donahue C; Balci S; Zee SY; Memis B; Shia J; Klimstra DS
    Virchows Arch; 2016 Nov; 469(5):523-532. PubMed ID: 27591765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas.
    Dal Molin M; Hong SM; Hebbar S; Sharma R; Scrimieri F; de Wilde RF; Mayo SC; Goggins M; Wolfgang CL; Schulick RD; Lin MT; Eshleman JR; Hruban RH; Maitra A; Matthaei H
    Hum Pathol; 2012 Apr; 43(4):585-91. PubMed ID: 21940037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
    Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
    J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm.
    Tanaka T; Kuroki T; Adachi T; Ono S; Hirabaru M; Soyama A; Kitasato A; Takatsuki M; Hayashi T; Eguchi S
    Pancreas; 2013 Apr; 42(3):488-93. PubMed ID: 23146920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma.
    Yopp AC; Katabi N; Janakos M; Klimstra DS; D'Angelica MI; DeMatteo RP; Fong Y; Brennan MF; Jarnagin WR; Allen PJ
    Ann Surg; 2011 May; 253(5):968-74. PubMed ID: 21422912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomere shortening and telomerase expression during multistage carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.
    Hashimoto Y; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Ohge H; Fukuda E; Shimamoto F; Sueda T; Hiyama E
    J Gastrointest Surg; 2008 Jan; 12(1):17-28; discussion 28-9. PubMed ID: 17960465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas.
    Ishida M; Egawa S; Aoki T; Sakata N; Mikami Y; Motoi F; Abe T; Fukuyama S; Sunamura M; Unno M; Moriya T; Horii A; Furukawa T
    Pancreas; 2007 Nov; 35(4):348-52. PubMed ID: 18090241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
    Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
    Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of microcystic, elongated, and fragmented glandular-like features in intraductal papillary mucinous neoplasm of the pancreas.
    Park JY; Lee JH; Song KB; Hwang DW; Kim KR; Kim SC; Hong SM
    Hum Pathol; 2018 Aug; 78():18-27. PubMed ID: 29410139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.